166398-34-1

Basic information

• Product Name: 1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBONITRILE
• Synonyms: 1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBONITRILE;6-TRIFLUORO-1,2,3,4-TETRAHYDROISOQUINOLINE;C90106;6-Isoquinolinecarbonitrile, 1,2,3,4-tetrahydro-;1,2,3,4-tetrahydro-6-isoquinolinecarbonitrile;1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBONITRILE-13;1,2,3,4-Tetrahydro-isoquinolin-6-carbonitrile
• CAS NO: 166398-34-1
• Molecular Formula: C₁₀H₁₀N₂
• Molecular Weight: 158.1998
• EINECS: -0
• Mol File: 166398-34-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 301.519 °C at 760 mmHg
• Flash Point: 136.154 °C
• Appearance: /
• Density: 1.148 g/cm³
• Vapor Pressure: 0.000103mmHg at 25°C
• Storage Temp.: 2-8°C
• PKA: 8.58±0.20(Predicted)
• CAS DataBase Reference: 1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBONITRILE(166398-34-1)
• EPA Substance Registry System: 1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBONITRILE(166398-34-1)

Safety Data

• Hazardous Substances Data: 166398-34-1(Hazardous Substances Data)

Usage

General Description

1,2,3,4-Tetrahydroisoquinoline-6-carbonitrile is a chemical compound, more specifically an organic alkaloid. The structure of this compound consists of a tetrahydroisoquinoline ring to which a cyano group is attached at the 6th position. Alkaloids, such as this compound, are commonly found in nature and are often used in medicine due to their wide pharmacological activities. Even though particular usage or applications specific to 1,2,3,4-tetrahydroisoquinoline-6-carbonitrile are not widely documented, its structural analogues are relevant in medicinal chemistry and drug discovery. As with any chemical compound, the handling and usage of 1,2,3,4-tetrahydroisoquinoline-6-carbonitrile should be accompanied by appropriate safety measures.

InChI:InChI=1/C10H10N2.ClH/c11-6-8-1-2-10-7-12-4-3-9(10)5-8;/h1-2,5,12H,3-4,7H2;1H

Upstream product

• 557-21-1 zinc(II) cyanide 
• 226942-29-6 6-bromo-1,2,3,4-tetrahydroisoquinoline 
• 166398-33-0 tert-butyl 6-cyano-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 893566-74-0 6-bromo-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 166398-33-0 tert-butyl 6-cyano-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1333995-67-7 5-(3-(2-(1,3-dihydroxypropan-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile 
• 1333996-68-1 5-(3-(2-(1,3-dihydroxypropan-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride 
• 1333996-67-0 5-(3-(2-(2,2-dimethyl-1,3-dioxan-5-yl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile 
• 1394241-55-4 C₁₇H₁₄N₂O₄S 
• 215790-38-8 trans-2-(2-(1-4-(N-tert-butyloxycarbonyl)amino)cyclohexyl)ethyl-6-cyano-1,2,3,4-tetrahydroisoquinoline 
• 1286750-76-2 sodium 3-(6-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-3,4-dihydroisoquinolin-2(1H)-yl)propanoate 
• 1286751-29-8 ethyl 3-(6-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-3,4-dihydroisoquinolin-2(1H)-yl)propanoate 
• 1286751-25-4 2-isopropoxy-5-(3-(1,2,3,4-tetrahydroisoquinolin-6-yl)-1,2,4-oxadiazol-5-yl)benzonitrile trifluoroacetate 

Relevant articles and documents

Ligand-based rational design, synthesis and evaluation of novel potential chemical chaperones for opsin

Inherited blinding diseases retinitis pigmentosa (RP) and a subset of Leber's congenital amaurosis (LCA) are caused by the misfolding and mistrafficking of rhodopsin molecules, which aggregate and accumulate in the endoplasmic reticulum (ER), leading to photoreceptor cell death. One potential therapeutic strategy to prevent the loss of photoreceptors in these conditions is to identify opsin-binding compounds that act as chemical chaperones for opsin, aiding its proper folding and trafficking to the outer cell membrane. Aiming to identify novel compounds with such effect, a rational ligand-based approach was applied to the structure of the visual pigment chromophore, 11-cis-retinal, and its locked analogue 11-cis-6mr-retinal. Following molecular docking studies on the main chromophore binding site of rhodopsin, 49 novel compounds were synthesized according to optimized one-to seven-step synthetic routes. These agents were evaluated for their ability to compete for the chromophore binding site of opsin, and their capacity to increase the trafficking of the P23H opsin mutant from the ER to the cell membrane. Different new molecules displayed an effect in at least one assay, acting either as chemical chaperones or as stabilizers of the 9-cis-retinal-rhodopsin complex. These compounds could provide the basis to develop novel therapeutics for RP and LCA.

Discovery of a brain-penetrant S1P3-sparing direct agonist of the S1P1 and S1P5 receptors efficacious at low oral dose

2-Amino-2-(4-octylphenethyl)propane-1,3-diol 1 (fingolimod, FTY720) has been recently marketed in the United States for the treatment of patients with remitting relapsing multiple sclerosis (RRMS). Its efficacy has been primarily linked to the agonism on

BASIC AMINE COMPOUND AND USE THEREOF

Novel amine compounds which are represented by the following formula (1) and efficacious against diseases such as a viral infectious disease with HIV, rheumatism, and cancer metastasis; typically, A 1 and A 2 represent a hydrogen atom or a substitutable monocyclic or polycyclic heteroaromatic ring and W represents a substitutable benzene ring or any group represented by the following formula (10) or (11): where X represents O, CH 2 , C(=O), NR 11 , or CHR 35 and D represents a group represented by the following formula (6): where Q represents a single bond, NR 12 , or a group represented by the formula (13): and Y represents a group represented by the following formula (7) : where z represents a substitutable monocyclic or polycyclic aromatic ring; and B represents -NR 25 R 26 ; and R 1 to R 26 in the above formulae represent a hydrogen atom, an alkyl group, an alkenyl group, or an alkynyl group.